Metsera Announces Positive Topline Phase 2a Clinical Data for Its Ultra-Long Acting GLP-1 Receptor Agonist, Met-097I
Metsera宣佈其超長效GLP-1受體激動劑Met-097I的積極二期a臨牀數據。
Metsera Announces Positive Topline Phase 2a Clinical Data for Its Ultra-Long Acting GLP-1 Receptor Agonist, Met-097I
Metsera宣佈其超長效GLP-1受體激動劑Met-097I的積極二期a臨牀數據。
使用瀏覽器的分享功能,分享給你的好友吧